Wednesday, March 29, 2023
Perspective, Therapeutics, Inc., a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents based in-part on IP licensed from UIRF, and an innovator in seed brachytherapy powering expanding treatment options for multiple cancers, announced the presentation of extremely encouraging results regarding 212Pb-VMT-α-NET, its lead preclinical candidate for neuroendocrine tumors (NET), currently being used therapeutically in India on a compassionate use basis.